Hepatitis B treatment and everyday impacts for migrants
Part of Digestive system, Infections clinical trials.
This study looks at how hepatitis B treatment affects everyday life—like work, relationships, and mental well-being—for people in migrant communities. Researchers will interview people who have never been treated and those who have been on treatment for over a year, to understand the challenges and benefits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic hepatitis B (a long-term infection).
- You are aged 18 or older.
- You are part of a migrant community (born outside the UK, or born in the UK but part of a migrant family).
- You can speak and understand English well enough to give consent.
- You either have never taken antiviral treatment for hepatitis B, or you have been on a daily oral antiviral for at least 12 months.
- You have not been diagnosed with liver cancer or a severe form of liver failure (decompensated cirrhosis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how patients with chronic hepatitis B are managed when they visit non-liver clinics. It aims to improve care and may also include a survey about quality of life for those starting treatment.
This “real-life” study follows people with chronic hepatitis B to better understand their health over time. It may help researchers learn which factors affect outcomes in everyday care.
This study looks at the genes of people with chronic hepatitis B (HBV) to find why some people's immune cells (B cells and NK cells) stop working properly. The goal is to discover new ways to treat the disease.
This study looks at people who have long-term hepatitis B and how they receive care in Australia. It may help improve understanding of what’s working in real life for patients like you.
This study tests whether a smartphone app called HBVCare helps patients with chronic hepatitis B stick to their treatment plans. Researchers will track how well the app helps patients take their medicines on time and understand what makes treatment adherence easier or harder.
This study looks at how to best use existing hepatitis B “nucleotide-analog” tablets in everyday care. It may help tailor when to start, and whether to continue or adjust treatment, based on your test results.
Hear when a new Hepatitis B Virus (HBV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.